Consent given pursuant to sections 14 and 14A for the importation and supply of the therapeutic goods specified - Link Medical Products Pty Ltd

Overview

The Therapeutic Goods Act 1989 was enacted to regulate the provision of therapeutic goods in Australia, ensuring that the public has access to safe and effective therapeutic products. This Act was introduced to address the need for a comprehensive framework governing the manufacturing, importation, supply, and advertising of therapeutic goods, thereby protecting public health. The Act is administered by the Therapeutic Goods Administration, an agency of the Department of Health. In this instance, on 20 February 2015, the delegate of the Secretary of the Department of Health granted consent under the Act for Link Medical Products Pty Ltd T/A Link Pharmaceuticals to import and supply hydralazine hydrochloride (APRESOLINE) 20 mg powder for injection ampoule, despite the product labels not fully complying with certain labelling requirements. The consent was issued with specific conditions to mitigate any potential risks to public health, including over-labelling with essential information and the provision of a ‘Dear Healthcare Provider’ letter to ensure healthcare professionals are adequately informed.

Scope and Application

The Therapeutic Goods Act 1989 governs the regulation of therapeutic goods in Australia, including medicines, medical devices, and blood and blood components. Section 14 and 14A of the Act, as applied by the Department of Health's Therapeutic Goods Administration, allows for the granting of consents to import and supply therapeutic goods that do not fully comply with certain regulatory requirements, provided that such consents are made subject to specific conditions. In this instance, the delegate of the Secretary of the Department of Health granted consent for the importation and supply of hydralazine hydrochloride (APRESOLINE) 20 mg powder for injection ampoules that do not conform to specific labelling requirements. This consent applies to Link Medical Products Pty Ltd T/A Link Pharmaceuticals and extends to the specified batch of hydralazine hydrochloride ampoules until the identified batch number is exhausted or expired. The consent is contingent on specific conditions being met, including the provision of additional labelling and information to healthcare providers to ensure patient safety and compliance with therapeutic goods standards.

Key Provisions

Sections 14 and 14A of the Therapeutic Goods Act 1989 (the "Act") provide the legal basis for the Therapeutic Goods Administration's (TGA) delegate to grant consent for the importation and supply of therapeutic goods that do not strictly comply with certain regulatory requirements. In this case, the delegate of the Secretary of the Department of Health has permitted Link Medical Products Pty Ltd, trading as Link Pharmaceuticals, to import and supply hydralazine hydrochloride (APRESOLINE) 20 mg powder for injection ampoules (AUST R 43190) that do not meet the labelling requirements specified in paragraphs 3(2)(g), (j) and 3(11)(c) of the Therapeutic Goods Order No. 69 (Order No. 69). Specifically, the consent allows for the supply of products whose labels do not include all relevant warnings, Australian approved storage conditions, and details of the Australian sponsor. This consent applies from 20 February 2015 until the exhaustion or expiry of batch number 140604, which expires in February 2019. The Act imposes several obligations on Link Medical Products Pty Ltd in relation to this consent. Firstly, the company must ensure that the labels provided with the letter of application contain dextrose instead of the Australian Approved Name (AAN) glucose. Secondly, the cartons of the product must be over-labelled with the AUST R number and the Australian sponsor’s details. Additionally, each affected batch must be accompanied by a 'Dear Healthcare Provider' letter that is identical to the one provided to the TGA with the letter of application. This letter should instruct healthcare providers to disregard the storage conditions and carton leaflet. A copy of the Australian approved Product Information document must also accompany each 'Dear Healthcare Provider' letter. Finally, the company must provide an assurance via electronic mail dated 20 February 2015 that the batch will comply with the Australian approved specifications. Importantly, no other changes to the product are permitted. Failure to comply with the conditions of this consent may result in legal consequences. While the specific offences and penalties are not detailed in the provided text, breaches of the Therapeutic Goods Act 1989 or the associated regulations generally carry significant penalties. These may include substantial fines, imprisonment, or both, depending on the severity and nature of the breach. The Therapeutic Goods Act 1989 and related legislation outline various offences related to the supply of therapeutic goods, including supplying goods that do not comply with regulatory standards. Therefore, it is crucial for Link Medical Products Pty Ltd to adhere strictly to the conditions outlined in the consent to avoid potential legal repercussions.